SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 15.63 |
| Enterprise Value ($M) | 10.37 |
| Book Value ($M) | 4.96 |
| Book Value / Share | 0.53 |
| Price / Book | 3.15 |
| NCAV ($M) | 4.96 |
| NCAV / Share | 0.53 |
| Price / NCAV | 3.15 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -1.36 |
| Return on Assets (ROA) | -0.91 |
| Return on Equity (ROE) | -1.03 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 9.43 |
| Current Ratio | 9.43 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 5.55 |
| Assets | 5.55 |
| Liabilities | 0.59 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | -7.24 |
| Net Income | -6.99 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -5.61 |
| Cash from Investing | 0.00 |
| Cash from Financing | 8.42 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G | Empery Asset Management, LP | 9.99 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 53,181 | 198,881 | 26.74 | |
| 91,030 | 251,783 | 36.15 | |
| 194,523 | 514,826 | 37.78 | |
| 340,020 | 1,085,820 | 31.31 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| BCDA – BioCardia, Inc. | BCLI – Brainstorm Cell Therapeutics Inc. |
| BCTX – BriaCell Therapeutics Corp. | BFRI – Biofrontera Inc. |
| BGM – BGM Group Ltd. |
Financial data and stock pages provided by
Fintel.io